Login / Signup

Adoptive Cell Therapy for Solid Tumors: Current Status in Melanoma and Next-Generation Therapies.

John B A G HaanenChristy LosGiao Q PhanAllison Betof Warner
Published in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting (2024)
Lifileucel or TIL has recently been FDA approved for metastatic melanoma patients as first cell therapy for a solid tumor. We discuss roll-out of TIL as new SOC and other upcoming new cell therapies.
Keyphrases
  • cell therapy
  • single cell
  • end stage renal disease
  • current status
  • chronic kidney disease
  • ejection fraction
  • stem cells
  • prognostic factors
  • patient reported outcomes